Ureteral Stent Placement After Ureteroscopy for Renal Stones: A Randomized Controlled Trial

Description

The rationale for this study is to determine if there is a difference in complications among patients undergoing ureteroscopy for renal stones who receive a stent compared to not receiving a stent postoperatively.Kidney stones affect 9% individuals within the United States, and the prevalence is increasing. Over the last few decades, ureteroscopy has become the most commonly performed stone procedure. However the complication rate after ureteroscopy is not insignificant. Reducing morbidity after ureteroscopy would improve patient outcomes and reduce health care utilization. A major contributor to patient morbidity after ureteroscopy is the ureteral stent, which is placed at the time of surgery and left in place 1-2 weeks after surgery. The rationale for utilizing stents is to prevent urinary obstruction from edema or stone fragments. On the other hand, stents cause hematuria, pain, and lower urinary tract symptoms. Additionally, stent-related symptoms are often misdiagnosed as urinary

Trial Eligibility

Inclusion Criteria: * nonobstructing renal stone 1.5cm total stone diameter (if multiple stones, then sum of maximum diameters) or less undergoing ureteroscopy Exclusion Criteria: * age \< 18 years * pregnancy status * ureteral stone * preoperative hydronephrosis * indwelling nephrostomy tube * planning bilateral ureteroscopy or subsequent staged ureteroscopy * solitary kidney or eGFR \<60 mL/min (CKD stage 3 or greater) * variant anatomy including horseshoe kidney, pelvic kidney, prior urinary tract reconstruction

Study Info

Interventions

Locations Recruiting

Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.